Emergency of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Machado, Elizabeth S ^a   Afonso, Adriana O ^a   Nissley, Dwight V ^b,c   Lemey, Philippe ^d,f   Cunha, Silvia M ^a   Oliveira, Ricardo H ^a   Soares, Marcelo A ^a,e  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^f REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CHILD; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE COUNT; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PHYLOGENY; POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN; ADULT; DISEASE TRANSMISSION; DRUG EFFECT; GENETIC SELECTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MISSENSE MUTATION; MULTIDRUG RESISTANCE; NEWBORN; POINT MUTATION; PREGNANCY; PREGNANCY COMPLICATION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIDANOSINE; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; MUTATION, MISSENSE; NELFINAVIR; PHYLOGENY; POINT MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SELECTION (GENETICS); ZIDOVUDINE;

EID: 62849128813     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004806     Document Type: Article

References (20)

1. Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, et al. (2002) Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV-1 transmission: a randomized trial. JAMA 288: 189-198.
2. Karchava M, Pulver W, Smith L, Philpott S, Sullivan TJ, et al. (2006) Prevalence of drug-resistance mutations and non-subype B strains among HIVinfected infants from New York State. J Acquir Immune Defic Syndr 42: 614-619.
3. Colgrove RC, Pitt J, Chung PH, Welled SL, Japour AJ (1988) Selective vertical transmission of HIV-1 antiretroviral resistance mutations. AIDS 12: 2281-2288.
4. Kamkamidze G, Sullivan T, Charbonneau T (2001) Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants. J Clin Virol 22: 143-148.
5. Bauer GR, Colgrove RC, LaRussa PS, Pitt J, Welles SL (2006) Antiretroviral resistance in viral isolates from HIV-1-transmitting mothers and their infants. AIDS 20: 1707-1712.
6. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, et al. (2001) Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15: 1951-1957.
7. Martinson NA, Morris L, Gray G, Moodley D, Pillay V, et al. (2007) Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 44: 148-153.
8. Johnson VA, Petropoulos CJ, Woods CR, Hazelwood JD, Parkin NT, et al. (2001) Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis 183: 1688-1693.
9. Schmitz T, Kleinkauf N, Klempa B, Ringe H, Varnholt V, et al. (2006) Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naïve mother to her child. Ped Infect Dis J 25: 275-276.
10. Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, et al. (2008) Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 82: 5510-5518.
11. Nissley DV, Garfinkel DJ, Strathern JN (1996) HIV reverse transcription in yeast. Nature 380: 330.
12. Nissley DV, Boyer PL, Garfinkel DJ, Hughes SH, Strathern JN (1998) Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A 95: 13905-13910.
13. Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, et al. (2006) Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 2612-2614.
14. Guindon S, Gascuel O (2003) A simple, fast, and accurate algorithm to estimate phylogenies by maximum likelihood. Syst Biol 52: 696-704.
15. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, et al. (2001) Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Non-nucleoside Reverse Transcriptase Inhibitor Therapy. J Virol 75: 4999-5008.
16. Llibre JM, Santos JR, Puig T, Moltó J, Ruiz L, et al. (2008) Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother 62: 909-913.
17. Iglesias-Ussel MD, Casado C, Yuste E, Olivares I, López-Galíndez C (2002) In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J Gen Virol 83: 93-101.
18. Wang J, Dykes C, Liang H, Wu H, Demeter L (2007) K101E, in combination with G190S, confers reduced fitness and efavirenz-dependent stimulation of HIV replication that are influenced by nucleoside resistance mutations and RT polymorphisms, 14th Conference on Retrovirus and Opportunistic infections. Los Angeles, CA, Abstract 599.
19. Metzner KJ, Rauch P, Walter H, Boesecke C, Zollner B, et al. (2005) Detection of minor populations of drug resistant HIV-1 in acute seroconverters. AIDS 19: 1819-1825.
20. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, et al. (2005) Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 19: 2167-2175.